Barinthus Biotherapeutics PLC
NASDAQ:BRNS

Watchlist Manager
Barinthus Biotherapeutics PLC Logo
Barinthus Biotherapeutics PLC
NASDAQ:BRNS
Watchlist
Price: 0.7028 USD -2.56% Market Closed
Market Cap: 28.7m USD

Barinthus Biotherapeutics PLC
Income from Continuing Operations

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Barinthus Biotherapeutics PLC
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Barinthus Biotherapeutics PLC
NASDAQ:BRNS
Income from Continuing Operations
-$61.2m
CAGR 3-Years
-6%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Income from Continuing Operations
-$235.8m
CAGR 3-Years
15%
CAGR 5-Years
-116%
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Income from Continuing Operations
-$250.7m
CAGR 3-Years
-35%
CAGR 5-Years
-46%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Income from Continuing Operations
-ÂŁ51.1m
CAGR 3-Years
27%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Income from Continuing Operations
ÂŁ19.3m
CAGR 3-Years
-19%
CAGR 5-Years
-12%
CAGR 10-Years
-7%
Oxford BioMedica PLC
LSE:OXB
Income from Continuing Operations
-ÂŁ39.1m
CAGR 3-Years
-14%
CAGR 5-Years
-25%
CAGR 10-Years
-15%
No Stocks Found

Barinthus Biotherapeutics PLC
Glance View

Market Cap
28.7m USD
Industry
Biotechnology

Vaccitech Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. The company is headquartered in Didcot, Oxfordshire and currently employs 107 full-time employees. The company went IPO on 2021-04-30. The company is focused on developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Its four platform technologies include ChAdOx, MVA, SNAP-TI, and SNAP-CI. The company is advancing a pipeline of five product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer, and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.

BRNS Intrinsic Value
Not Available

See Also

What is Barinthus Biotherapeutics PLC's Income from Continuing Operations?
Income from Continuing Operations
-61.2m USD

Based on the financial report for Dec 31, 2024, Barinthus Biotherapeutics PLC's Income from Continuing Operations amounts to -61.2m USD.

What is Barinthus Biotherapeutics PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-22%

Over the last year, the Income from Continuing Operations growth was 17%. The average annual Income from Continuing Operations growth rates for Barinthus Biotherapeutics PLC have been -6% over the past three years , -22% over the past five years .

Back to Top